Latest Ratios: P/E Ratio -1.1x · EV/EBITDA N/A · ROE -191.4%. (2017–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $13M | $14M | $5M | $5M | $9M | $15M | $29M | $57M | — | — |
| Enterprise Value | $7M | $7M | $-2238590 | $-4327953 | $3M | $6M | $27M | $55M | — | — |
| P/E Ratio → | -1.07 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 2.17 | 2.22 | 0.69 | 0.51 | 1.82 | 1.49 | 6.31 | 23.68 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -191.4% | -191.4% | -99.8% | -107.0% | -151.6% | -197.1% | -204.4% | -603.2% | -372.6% | -170.2% |
| ROA | -162.8% | -162.8% | -91.2% | -92.3% | -128.2% | -176.4% | -178.2% | -460.7% | -287.2% | -163.3% |
| ROIC | — | — | -7169.5% | — | -44786.5% | -629.5% | -402.5% | -2003.9% | — | — |
| ROCE | -170.5% | -170.5% | -99.9% | -103.0% | -142.9% | -187.4% | -199.3% | -604.9% | -372.6% | -158.0% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.00 | 0.01 | — | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.01 | -1.02 | -0.97 | -1.26 | -0.86 | -0.57 | -0.71 | -1.82 | -1.04 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | -36.24 | — | — | — | — | — |
Net cash position: cash ($6M) exceeds total debt ($5678)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.72 | 4.72 | 9.20 | 14.96 | 4.85 | 12.19 | 15.32 | 5.99 | 1.44 | 24.87 |
| Quick Ratio | 4.72 | 4.72 | 9.20 | 14.96 | 4.85 | 12.19 | 15.32 | 5.99 | 1.44 | 24.87 |
| Cash Ratio | 4.30 | 4.30 | 8.47 | 13.69 | 4.78 | 12.02 | 15.03 | 5.67 | 0.81 | 24.87 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $14M | $6M | $3M | $1M | $893203 | $494513 | $366583 | $376982 | $384482 |
Clinical trial funding shortfall
According to recent market data, Hoth Therapeutics trades at a price-to-book ratio of 2.13, a valuation that appears to discount the firm's lack of commercial revenue and instead assigns value primarily to the speculative potential of its early-stage, licensed academic intellectual property pipeline.
The absence of meaningful P/E or EV/EBITDA multiples underscores the company's pre-revenue status, forcing investors to rely on book value as a proxy for liquidation worth rather than earnings power. This valuation suggests the market is pricing in a high probability of future equity dilution, as the current market capitalization remains sensitive to the binary outcomes of clinical trial readouts.
Based on reported figures, Hoth Therapeutics has experienced a severe decay in return on invested capital, with ROIC plummeting to -171.6% in 2026Q1, illustrating the significant challenge of generating positive returns while the company remains in a capital-intensive, pre-commercial research and development phase.
The persistent negative ROIC trends, compared to historical performance, indicate that the firm is currently destroying capital rather than compounding it through its licensing-heavy model. This suggests that until the company can successfully transition to a royalty-generating entity, the efficiency of its invested capital will remain fundamentally impaired by high fixed R&D costs.
As reported in financial statements, the company's current ratio has contracted significantly from 27.57 in 2025Q2 to 3.39 in 2026Q1, signaling a rapid erosion of the liquidity buffer necessary to sustain ongoing clinical research activities without immediate access to external capital markets.
While a current ratio of 3.39 might appear adequate in isolation, the lack of recurring revenue means this liquidity is strictly finite and subject to rapid depletion. Investors should monitor the burn rate closely, as the current trajectory suggests that the firm's ability to meet its near-term research obligations is becoming increasingly dependent on dilutive financing.
As indicated by the company's financial history, the use of traditional P/E or EBITDA multiples is fundamentally misapplied to Hoth Therapeutics, as these metrics obscure the firm's true value, which resides in the optionality of its licensed academic pipeline rather than current operational profitability.
Analysts should instead focus on 'cash-plus-pipeline' metrics or the probability-weighted net present value of future milestone payments. Relying on earnings-based ratios for a clinical-stage firm creates a misleading picture of financial health, as it fails to account for the non-linear, binary nature of biotech development cycles.
Includes 30+ ratios · 9 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying HOTH stock.
Hoth Therapeutics, Inc.'s current P/E ratio is -1.1x. This places it at the 50th percentile of its historical range.
Hoth Therapeutics, Inc.'s return on equity (ROE) is -191.4%. The historical average is -186.8%.
Based on historical data, Hoth Therapeutics, Inc. is trading at a P/E of -1.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.